|
|
|
| Clinical Study of Ai Sciplan combined with Ozagrel in the treatment of Acute Cerebral Infarction with Anxiety and Depression |
| YIN Yanling, WANG Yanfei, MA Juan, et al |
| Xi'an Third Hospital, Shaanxi Xi'an 710018, China |
|
|
|
|
Abstract Objective: To explore clinical study of escitalopram combined with ozagrel sodium in the treatment of acute cerebral infarction (ACI) combined with anxiety and depression. Methods: The subjects were 110 ACI patients with anxiety and depression admitted to our hospital from February 2015 to November 2017. They were divided into control group and observation group by random number table, each of 55 cases. The control group was treated with ozagrel sodium and the observation group was treated with escitalopram on the basis of it. All the patients were treated for 12 weeks. The clinical effects of the two groups were compared. The changes of the related scales (NIHSS, Barthel index, SAS and SDS), the levels of neuropeptide Y (NPY), substance P (SP) and the adverse reactions were observed before and after treatment. Results: After 12 weeks treatments, the total effective rate of observation group was higher than that of control group, and there was statistical difference (94.55% VS 74.55%, P<0.05). Observation group's NIHSS, SAS and SDS scores and serum SP levels were significant lower than those in control group at same time (P<0.05), BI score and serum NPY level were significant higher (P<0.05). Here was no significant difference in the incidence of adverse reactions between two groups (41.42% VS 36.36%, P>0.05). Conclusion: Escitalopram combined with ozagrel sodium helps patients with ACI combined with anxiety and depression to adjust psychological state, promote the recovery of nerve function with accurate effect. It is safe and reliable.
|
|
|
|
|
|
[1] 骆嵩,屈洪党,刘晓林,等.磁敏感加权成像早期评价急性脑梗死患者预后及脑血容量的相关性分析[J].蚌埠医学院学报,2016,41(4):462~463.
[2] 张岩,李军.奥扎格雷治疗急性脑梗死52例[J].中国药业,2015,24(7):116.
[3] Swartz RH, Bayley M, Lanctot KL, et al. Post-stroke depression, obstructive sleep apnea, and cognitive impairment: rationale for, and barriers to, routine screening [J]. International Journal of Stroke, 2016, 11 (5): 509.
[4] Baldwin DS, Asakura S, Koyama T, et al. Efficacy of escitalopram in the treatment of social anxiety disorder: a meta-analysis versus placebo [J]. European Neuropsychopharmacology the Journal of the European College of Neuropsychopharmacology, 2016 , 26 (6) :1062~1069.
[5] 职瑾,裴纪文,段斌,等.黛力新联合逍遥丸治疗脑梗死后焦虑抑郁患者临床观察[J].世界中西医结合杂志,2014,9(11):1206.
[6] Quaranta D, Marra C, Gainotti G. Post-stroke depression: Main phenomenological clusters and their relationships with clinical measures [J]. Behavioural Neurology, 2016, 25 (4): 303~310.
[7] 胡新永,姬利,殷成龙,等.奥扎格雷钠联合黛力新治疗脑梗死后抑郁、焦虑的临床效果[J].国际精神病学杂志,2016,43(2):304~306.
[8] 杨欢,王丽,王小平,等.脑卒中后急性期抑郁及焦虑发生率及相关因素调查[J].中华全科医学,2015,13(4):624~626.
[9] Angermann CE, Gelbrich G, Stork S, et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: The MOOD-HF randomized clinical trial [J]. Jama, 2016, 315 (24): 2683.
[10] 廖继武,黄俏庭,潘集阳,等.原发性失眠患者与有失眠症状抑郁症患者的血清神经肽Y和P物质水平[J].中国心理卫生杂志,2012,26(7):490~494. |
|
|
|
2018, Vol. 24 
